5bni
From Proteopedia
(Difference between revisions)
(4 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Porcine CD38 complexed with complexed with a covalent intermediate, ribo-F-ribose-5'-phosphate== | |
+ | <StructureSection load='5bni' size='340' side='right'caption='[[5bni]], [[Resolution|resolution]] 2.50Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[5bni]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Sus_scrofa Sus scrofa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5BNI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5BNI FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.5Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=AVW:[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHYL+[(2R,3R,4S)-4-FLUORO-3-HYDROXYTETRAHYDROFURAN-2-YL]METHYL+DIHYDROGEN+DIPHOSPHATE'>AVW</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5bni FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5bni OCA], [https://pdbe.org/5bni PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5bni RCSB], [https://www.ebi.ac.uk/pdbsum/5bni PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5bni ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Cyclic ADP-ribose (cADPR) mobilizes intracellular Ca(2+) stores and activates Ca(2+) influx to regulate a wide range of physiological processes. It is one of the products produced from the catalysis of NAD(+) by the multifunctional CD38/ADP-ribosyl cyclase superfamily. After elimination of the nicotinamide ring by the enzyme, the reaction intermediate of NAD(+) can either be hydrolyzed to form linear ADPR or cyclized to form cADPR. We have previously shown that human CD38 exhibits a higher preference towards the hydrolysis of NAD(+) to form linear ADPR while Aplysia ADP-ribosyl cyclase prefers cyclizing NAD(+) to form cADPR. In this study, we characterized the enzymatic properties of porcine CD38 and revealed that it has a prominent secondary NAD(+) cyclase activity producing cADPR. We also determined the X-ray crystallographic structures of porcine CD38 and were able to observe conformational flexibility at the base of the active site of the enzyme which allow the NAD(+) reaction intermediate to adopt conformations resulting in both hydrolysis and cyclization forming linear ADPR and cADPR respectively. | ||
- | + | Porcine CD38 exhibits prominent secondary NAD(+) cyclase activity.,Ting KY, Leung CF, Graeff RM, Lee HC, Hao Q, Kotaka M Protein Sci. 2016 Mar;25(3):650-61. doi: 10.1002/pro.2859. Epub 2016 Jan 12. PMID:26660500<ref>PMID:26660500</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
- | [[Category: | + | <div class="pdbe-citations 5bni" style="background-color:#fffaf0;"></div> |
- | [[Category: | + | == References == |
- | [[Category: Kotaka | + | <references/> |
- | [[Category: | + | __TOC__ |
- | [[Category: | + | </StructureSection> |
- | [[Category: | + | [[Category: Large Structures]] |
+ | [[Category: Sus scrofa]] | ||
+ | [[Category: Graeff RM]] | ||
+ | [[Category: Hao Q]] | ||
+ | [[Category: Kotaka M]] | ||
+ | [[Category: Lee HC]] | ||
+ | [[Category: Leung CFP]] | ||
+ | [[Category: Ting KY]] |
Current revision
Porcine CD38 complexed with complexed with a covalent intermediate, ribo-F-ribose-5'-phosphate
|
Categories: Large Structures | Sus scrofa | Graeff RM | Hao Q | Kotaka M | Lee HC | Leung CFP | Ting KY